Performance assessment of a new serological diagnostic test for COVID-19 with candidate peptides from spike and nucleocapsid viral proteins.

Autor: Cavalcanti-Dantas VM; Laboratory of Virology and Experimental Therapy, Department of Virology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation (Fiocruz), Recife, Pernambuco, Brazil., da Silva AF; Laboratory of Experimental Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil., Mendes AF; Laboratory of Microbiology, Department of Microbiology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation (Fiocruz), Recife, Pernambuco, Brazil., de Araújo Júnior WO; Laboratory of Immunology and Hematology, Department of Physiology and Pathology, Multidisciplinary Research Group in Biotechnology and Health (GePeMBiS), Federal University of Paraiba, João Pessoa, Paraíba, Brazil., Bernardo-Menezes LC; Laboratory of Virology and Experimental Therapy, Department of Virology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation (Fiocruz), Recife, Pernambuco, Brazil., Bresani-Salvi CC; Laboratory of Virology and Experimental Therapy, Department of Virology, Group of Integrated Studies in Nutrition and Health, Aggeu Magalhães Institute, Oswaldo Cruz Foundation (Fiocruz), Instituto de Medicina Integral Prof Fernando Figueira, Recife, Pernambuco, Brazil., Castellano LRC; Professional and Technological Center of the Technical School of Health, Federal University of Paraiba, João Pessoa, Paraíba, Brazil., Fernandes AIV; Health Promotion Department of the Medical Sciences Center and Division for Infectious and Parasitic Diseases, Lauro Wanderley University Hospital, Federal University of Paraiba, João Pessoa, Paraíba, Brazil., Lemos SG; Advanced Study Group in Analytical Chemistry, Department of Chemistry, Federal University of Paraiba, João Pessoa, Paraíba, Brazil., de Magalhães JJF; Laboratory of Virology and Experimental Therapy, Department of Virology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation (Fiocruz), Recife, Pernambuco, Brazil., Oliveira RADS; Laboratory of Immunology and Hematology, Department of Physiology and Pathology, Multidisciplinary Research Group in Biotechnology and Health (GePeMBiS), Federal University of Paraiba, João Pessoa, Paraíba, Brazil., de Assis PAC; Laboratory of Immunology and Hematology, Department of Physiology and Pathology, Multidisciplinary Research Group in Biotechnology and Health (GePeMBiS), Federal University of Paraiba, João Pessoa, Paraíba, Brazil., de Souza JR; Laboratory of Immunology and Hematology, Department of Physiology and Pathology, Multidisciplinary Research Group in Biotechnology and Health (GePeMBiS), Federal University of Paraiba, João Pessoa, Paraíba, Brazil., de Morais CNL; Laboratory of Virology and Experimental Therapy, Department of Virology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation (Fiocruz), Recife, Pernambuco, Brazil. clarice.lins@fiocruz.br.
Jazyk: angličtina
Zdroj: Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] [Braz J Microbiol] 2024 Sep; Vol. 55 (3), pp. 2797-2803. Date of Electronic Publication: 2024 Jul 23.
DOI: 10.1007/s42770-024-01446-3
Abstrakt: Numerous commercial tests for the serological diagnosis of COVID-19 have been produced in recent years. However, it is important to note that these tests exhibit significant variability in their sensitivity, specificity, and accuracy of results. Therefore, the objective of this study was to utilize bioinformatics tools to map SARS-CoV-2 peptides, with the goal of developing a new serological diagnostic test for COVID-19. Two peptides from the S protein and one from the N protein were selected and characterized in silico, chemically synthesized, and used as a serological diagnostic tool to detect IgM, IgG, and IgA anti-SARS-CoV-2 antibodies through the ELISA technique, confirmed as positive and negative samples by RT-qPCR or serology by ELISA. The results showed a sensitivity, specificity, Positive Predictive Value and Negative Predictive Value of 100% (p < 00001, 95% CI) for the proposed test. Although preliminary, this study brings proof-of-concept results that are consistent with the high-performance rates of the ELISA test when compared to other well-established methods for diagnosing COVID-19.
(© 2024. The Author(s) under exclusive licence to Sociedade Brasileira de Microbiologia.)
Databáze: MEDLINE
Externí odkaz: